A synbiotic intervention shut down gut epithelial permeability, markedly decreasing systemic inflammation and cardiac structural changes in a clinical scale model of cardiometabolic syndrome.
Does a synbiotic intervention improve gut epithelial permeability, systemic inflammation, and cardiac structural changes in a clinical scale model of cardiometabolic syndrome?
Targeting the gut-heart axis with a synbiotic intervention improves gut barrier function, systemic inflammation, and cardiac remodeling in a preclinical model of cardiometabolic syndrome, suggesting a potential therapeutic avenue for HFpEF.
Poor diet, gut dysbiosis, and systemic inflammation constitute a gut-heart axis (GHA) that may affect heart failure with preserved ejection fraction. Clinical scale models to interrogate this axis are limited. Here, we show the full extent of the GHA-gut barrier function loss, systemic and microvascular inflammation, and its colocalization with apoptosis (left atrium) and hypertrophy (left ventricle). Gut barrier function primacy in regulating the GHA is supported by a synbiotic intervention that shuts down gut epithelial permeability, markedly decreasing systemic inflammation and, remarkably, cardiac structural changes in left heart chambers. These data support a new paradigm for targeting heart failure with preserved ejection fraction via the GHA.
Herisson et al. (Wed,) conducted a other in Cardiometabolic Syndrome / Heart failure with preserved ejection fraction. Synbiotic intervention was evaluated on Gut epithelial permeability, systemic inflammation, and cardiac structural changes. A synbiotic intervention shut down gut epithelial permeability, markedly decreasing systemic inflammation and cardiac structural changes in a clinical scale model of cardiometabolic syndrome.